Current Clinical Trials in Infectious Diseases
Our Clinical Trial Research
Members of the Division of Infectious Diseases conduct impactful, internationally recognized research in multiple realms of infectious diseases, epidemiology, global health, and health disparities research. Our specific strengths include basic and translational research in immunology, inflammatory response and invasive fungal infections, quality improvement, infection control, and community-partnered research to address health disparities in HIV and COVID-19.
We are partners in international COVID-19 and vaccine trials networks funded by the NIH and the Bill and Melinda Gates Foundation. Our clinical trials unit leads multiple clinical trials of therapeutic agents for COVID-19, fungal disease, and vaccines. Our learners, including infectious diseases fellows, residents, and students, are an integral part of our efforts as we foster the next generation of infectious diseases researchers.
Studies with Open Enrollment (Recruiting)
ACTIV-6
Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
RECOVER
Post Acute Sequelae of SARS-COV2 (PASC)
Cardiol
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Pending – Starting Soon
Closed to Enrollment – Ongoing
Novavax
Evaluating efficacy of 2-dose regiment of SARS-CoV-2 rS
Phase 1 mRNA HIV Vaccine Trial
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
Completed Studies
ACTT
Adaptive COVID Treatment Trial
ACTIV-1 IM
Evaluate efficacy of Remdesivir
BET (ACTIV-5)
Evaluate clinical efficacy of Lenzilumab/Remdesivir vs placebo/Remdesivir
CAPA
COVID-19 Associated Pulmonary Aspergillosis
DISRUPT
Direct Lysis of Staph aureus Resistant Pathogen Trial
F2G
Open label olorofim
LYT-100
Also known as RECLAIN
Remdesivir Use in Kidney Failure
Evaluate efficacy of 5B-Lenzilumab/Remdesivir vs Placebo/Remdesivir
Repository
COVID-19 specimens
IAVI HIV Vaccine
Outpatient, phase 1 prevention
Invasive Aspergillosis Complicating Severe Influenza
Non-clinical trial
LANCER
CardiolRx in pts with COVID-19 & CVD or CVD Risk Factors